Alteration of DNMT1/DNMT3A by eribulin elicits global DNA methylation changes with potential therapeutic implications for triple-negative breast cancer

Triple-negative breast cancer (TNBC) is an aggressive disease subtype with limited treatment options. Eribulin is a chemotherapeutic approved for the treatment of advanced breast cancer that has been shown to elicit epigenetic changes. We investigated the effect of eribulin treatment on genome-scale...

Descripción completa

Detalles Bibliográficos
Autores principales: Bagheri, Meisam, Lee, Min Kyung, Muller, Kristen E., Miller, Todd W., Pattabiraman, Diwakar R., Christensen, Brock C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10274899/
https://www.ncbi.nlm.nih.gov/pubmed/37333096
http://dx.doi.org/10.1101/2023.06.09.544426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10274899/
https://www.ncbi.nlm.nih.gov/pubmed/37333096
http://dx.doi.org/10.1101/2023.06.09.544426

Ejemplares similares